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Summary Menadione (Vitamin K3) has anti-tumoral
effects against a wide range of cancer cells. Its potential
toxicity to normal cells and narrow therapeutic range limit
its use as single agent but in combination with radiation or
other anti-neoplastic agents can be of therapeutic use. In
this paper, we first evaluated the early (within 3 h) effect of
menadione on ongoing DNA replication. In normal rat
cerebral cortex mini-units menadione showed an age
dependent anti-proliferative effect. In tissue mini-units
prepared from newborn rats, menadione inhibited ongoing
DNA replication with an IC 50 of approximately 10 μM but
50 μM had no effect on mini-units from prepared adult rat
tissue. The effect of short (72 h) and prolonged exposure
(1–2 weeks) to menadione alone in the DBTRG.05MG
human glioma cells line and in combination with vitamin C
was studied. After short period of exposure data show that
menadione alone or in combination with vitamin C
provided similar concentration-response curves (and IC50
values). Prolonged exposure to these drugs was evaluated
by their ability to kill 100% of glioma cells and prevent
regrowth when cells are re-incubated in drug-free media. In
this long-term assay, menadione:vitamin C at a ratio 1:100
showed higher anti-proliferative activity when compared to
each drug alone and allowed to reduce each drug
concentration between 2.5 to 5-fold. Similar anti-
proliferative effect was demonstrated in 8 patient derived
glioblastoma cell cultures. Our data should be able to
encourage further advanced studies on animal models to
evaluate the potential use of this combination therapy for
glioma treatment.
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Introduction
Menadione (2-methyl-1, 4 naphthoquinone: vitamin K3)
inhibits the growth of mammalian tumor cells both in vitro
and in vivo, e.g. mouse or rat liver tumors, glioma,
melanoma and neuroblastoma, cells [1, 2], human glioma
[3], hepatoma cells [4] and urologic tumors [5]. Moreover,
a potentiation of radiotherapy by vitamin K has been shown
[2] as well as a synergistic effect when given in
combination with other anti-tumor agents [6]. Menadione
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DOI 10.1007/s10637-010-9489-0has also effects on MDR1-expressing cancer cells both in
culture and animal model systems [7]. It has been suggested
that the cytotoxic effect of menadione is related to the
generation of reactive oxygen species (ROS) by enzymatic
reaction during its metabolism [8]. Menadione can gen-
erates ROS by non-enzymatic reaction with protein thiols in
plasma [9]. Consistent with this observation, the thiol-
depleting agent N-ethylmaleimide (NEM) suppresses
menadione-induced ROS generation and cytotoxicity to
platelet. Menadione was also found to inhibit topoisomer-
ase II [10], DNA polymerase gamma [11] and binds to
tubulin, disrupting the microtubule networks [12]. Menadi-
one, being a small lipid soluble molecule (M.W. 172.2 Da)
is a potential drug for the treatment of brain tumors. As
pointed out by Pardridge [13], only lipid soluble molecules
with a molecular mass less than 400–600 Da are capable of
crossing the blood brain barrier (BBB). The anti-
proliferative effect of menadione has been investigated in
several glioma cell cultures using classical short term (24–
72) proliferation assays. In this type of assays, the
concentration that inhibits proliferation by 50% (IC50)i s
the endpoint parameter usually measured. For most drugs,
even at concentrations higher than the IC50, the short
exposure time does not kill 100% of cells and the IC100 (or
lethal concentration 100, LC100) is calculated by interpola-
tion. In most studies, the fate of surviving cells after short
term incubation with drugs is not evaluated. For instance,
glioma cells can survive prolonged exposure of anti-
neoplastic drugs at concentrations much higher than the
IC50 [14]. At the clinical level, these surviving cells explain
the relapse of tumor when the treatment is discontinued and
suggest that drugs that kill 100% of tumoral cells (“pan-
killers”) will be more effective anti-cancer drugs and may,
cure cancer. To circumvent this limitation, we recently
postulated that long-proliferation assays and the determina-
tion of the minimum concentration and time necessary to
kill cancer cells completely and prevent regrowth when the
drug is removed from the culture (called Regrowth
Concentration Zero, RC0) might help to improve the
success of anti-cancer drugs entering clinical trials. In this
study, we investigated the anti-proliferative effect of short
and prolonged exposure of menadione on glioma cells. We
found in the current study that menadione is an effective
“pankiller” and its cytotoxic effect can be potentiated when
used in combination with vitamin C.
Materials and methods
Reagents and enzymes
Dimethylsulfoxide (DMSO), menadione and vitamin C
were purchased from Sigma (Sweden). Dulbecco modified
Eagle’s medium with glutamine and 4500 mg/l D-glucose
(DMEM) and (Iscove's modified Dulbecco medium)
IMDM were purchased from GIBCO/Life-technologies
(Sweden). [methyl-
3H]-thymidine (86.0 Ci/mmol) was
purchased from Amersham (U.K.). All other reagents were
of analytical grade or the highest grade available.
Cell lines
Stock cultures of human DBTRG-05MG glioma cell line
were obtained from the European Collection of Cell Culture
(ECACC). Cells were routinely cultured as previously
described [14]. Patients-derived glioblastoma cells
hGCL1- hGCL8 were kindly provided by Dr Peter Siesjö
(Lund University). The usage of patient glioblastoma
multiforme tumor samples has been accepted by the Local
Ethical Board of the University of Lund.
Preparation of drugs
Menadione was prepared as stock solutions (100 mM) in
DMSO and stored at −20°C. Vitamin C was diluted in
distilated sterile water and stored at −20°C as 500 mM
stock solution. The final dilutions were done in culture
media, keeping the DMSO concentration below 1% (v/v).
Experimental procedures
Determination of ongoing DNA replication
Generation of tissue mini-units, determination of [methyl-
3H]-thymidine incorporation into DNA and ongoing DNA
synthesis rate, protein quantitation and determination of
effect of menadione were performed as previously reported
[15, 16]. Briefly, mini-units of normal rat cerebral tissue
were generated immediately after killing the animals. These
mini-units were then incubated in microwell plates (Nunc,
Denmark) with DMEM containing 2 μCi/ml [methyl-3H]-
thymidine and drugs at the appropriate concentration or
their corresponding vehicle (DMSO or H2O). Each exper-
imental point was determined by at least quadruplicate. The
DNA synthesis rate was calculated as cpm/mg of protein/
min. The effect of drugs was determined as change (%) of
DNA synthesis rate compared to the corresponding control
or percentage of control DNA synthesis rate. Animal
experiments were approved by the Animal Ethical Com-
mittee at Huddinge University Hospital, Sweden.
Short term proliferation assay: Cell were plated in 96
well microplates (~5,000 cell/well) and allowed to adhere
overnight. Drugs at the appropriate concentration were
added and incubated for 72 h. Cell viability was measured
by the cell counting kit (CCK Kit) (Sigma, Sweden)
following manufacturer’s instructions.
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on cell cultures, cells were plated in 96 well microplates
(~5,000 cell/well) and allowed to grow for 3–4 days. Drugs
wereaddedandmaintainedfor2weeks(mediaanddrugswere
changed twice a week). After 2 weeks, cells were incubated in
drug-free media (changed twice a week) for 2–4 weeks.
Regrowth was evaluated using a routine inverted microscope.
Results
Age dependent inhibition of DNA synthesis by menadione
in normal rat cerebral cortex
The results obtained from tissue mini-units prepared from
5 days old rats showed a dose-dependent inhibition of the
DNA synthesis in menadione treated mini-units (IC50≅
10 μM) (Fig. 1a). This inhibitory effect was of short time
onset as well as time-dependent since the inhibitory effect
of 50 μM menadione at 30 and 60 min were 34,66±2,90%
and 84,36±2,25% respectively (data not shown). When
tissue mini-units were prepared from adult rats (>60 days
old), menadione (50 μM) failed to decrease the rate of
DNA synthesis (Fig. 1b). When uptake experiments were
performed (see “Materials and methods”), menadione
(50 μM) did not inhibit the cellular uptake of [meth-
yl-
3H]-thymidine prior to incorporation into DNA (Fig. 1c).
Further, the reversibility of menadione effect on the
incorporation [methyl-
3H]-thymidine into DNA showed
that, a) 60 min of pre-incubation with menadione gave a
strong (84,36±2,25%) inhibition of DNA synthesis
(Fig. 1d, grey columns), and b) removal of menadione
from the medium failed to recover the capacity of the tissue
to incorporate the radioactive precursor into DNA (Fig. 1d,
black columns). In all cases, DMSO was used as control in
concentrations below 1% (v/v) since it has been shown that
DMSO at concentrations up to 1% (v/v) for 3 h has no
effect on DNA synthesis rate.
Effect of menadione on DBTRG.05MG human glioma cells
TherelativelackofinhibitionbymenadioneonongoingDNA
synthesis inadult normalrat cerebralcortex suggested that the
drug might be useful as anticancer drugs for brain tumors in
adultsbecauseofpotentiallowertoxicitytonormalcells.Inan
adult animal model of glioma, we previously showed that the
ongoing DNA synthesis rate was relatively high in tumor
tissue compared to normal brain tissue [17]. Unfortunately,
the tissue mini-unit system does not allow the study of
prolonged drug incubation time. For this reason we next
evaluated the anti-proliferative effect of menadione on the
human DBTRG.05MG glioma cells using a standard short
term (72 h) proliferation assay. Since menadione effect might
be serum dependent we performed concentration- responses
experiments in serum-free as well as serum-containing
media. Menadione alone inhibits cell proliferation with
similar efficiency in both media (data not shown). Vitamin
C alone in the range 0.1-5 mM slightly inhibited cell
proliferation and the combination of both drugs in the ratio
1:100 (e.g. menadione 1 μM + Vitamin C 0.1 M) showed
modest increase in potency compared to menadione alone
(Fig. 2).
In order to evaluate the effect of long term incubation of
these drugs, DBTRG.05MG cells were incubated with
different concentrations of each drug alone or in combina-
tion for 2 weeks as described in Materials and Methods and
the RC0 parameter was determined. Menadione (1–25 μM)
alone or vitamin C alone (0.1–2.5 mM) failed to kill 100%
of glioma cells: a small fraction of cells survived up to
1 week exposure and were able to resume growth when
cells were cultured in drug-free media (Fig. 3 Top). To
prevent regrowth of DBTRG.05MG cells, menadione at
50 μMf o ro n ew e e k( F i g .3 Middle) or 25 μM for 2 weeks
(data not shown) were required. Vitamin C alone failed to
prevent regrowth unless a very high concentration (> 5 mM)
for 1 week was used (Fig. 3 Top and Middle). When used in
combination at relatively low doses (M:VC at 10 μM:1 mM)
for one week M:VC was able to prevent regrowth (Fig. 3
Bottom). Thus, the M:VC combination is a “pankiller” being
able to prevent regrowth of glioma cells when the drug is
removed from the media.
Menadione:vitamin C (10 μM:1 mM) shows similar
antiproliferative activity in a panel of 8 patient derived cell
cultures
In order to evaluate the possibility that menadione:vitamin
C might show differential potency for other glioma cells,
we investigated the effect of selected drug treatment in a
panel of 8 different patient derived cell cultures (hGCL1-8,
Table 1). Short term assays (72 h) showed modest or no
difference between menadione alone and menadione
+vitamin C. In long-term proliferation assays, despite the
fact that some glioma cells were slightly resistant to
menadione alone (e.g. few live cells were present after
2 weeks of menadione treatment with 25–50 μM) the M:
VC combination for 1 week (10 μM:1 mM) was able to
prevent the regrowth of all cell cultures when the drug was
removed from the culture (Table 1).
Discussion
In the present study, we first showed an age-dependent
inhibitory effect of menadione on normal rat cerebral cortex
(Fig. 1) suggesting that menadione might preferentially kill
1316 Invest New Drugs (2011) 29:1314–1320fast proliferating cells. Since glioma mostly occurs in the
adult population where menadione toxicity to normal tissue
might be low, menadione can be exploited to kill fast
proliferating tumor cells with relatively low toxicity to slow
proliferating normal cells. Indeed, while 50 μM menadione
showed no effect on ongoing DNA replication in adult
normal rat cerebral cortex (Fig. 1), the IC50 for the human
DBTRG.05MG glioma line and patient-derived glioma
cells was in the 10–25 μM range (Figs. 2 and 4). In our
study, the data obtained from the tissue mini-unit system
and the cell lines cannot be compared because they are
different experimental systems and different exposure times
were used. However, several groups had reported that low
menadione concentration (10–50 μM) are relatively well
tolerated by normal glial cells [18, 19]. The tissue mini-unit
system preserves the metabolic and proliferative properties
of the tissue in situ and thus, suggests that menadione might
be also less toxic for other neural cell types on adult tissue
compared to young brain tissue. The early effect of
menadione on ongoing DNA replication was irreversible
(Fig. 1d), suggesting that the drug does not need to be
continuously present to exert its anti-proliferative effect.
Before clinical trials, toxicity to other normal neural cell
types (neurons and neural stem cells) should be evaluated.
Unfortunately, the tissue mini-unit system does not allow
the evaluation of prolonged drug exposure and our assay
Fig. 1 Age-dependent inhibitory effect of menadione on normal rat
cerebral cortex. a Concentration-dependent effect of menadione on
DNA synthesis in tissue mini-units prepared from 5 days old rat
cerebral cortex. b Effect of menadione (50 μM) on DNA synthesis in
tissue mini-units prepared from >60 days postnatal rat cerebral cortex.
Control mini-units (expressed as: 100% DNA synthesis) were
incubated with equivalent concentrations of vehicle (0.2% DMSO). c
Effect of menadione on [methyl-
3H]-thymidine uptake. The tissue
mini-units prepared from the cerebral cortex from 5 days postnatal age
rats were incubated with 50 μM menadione or equivalent concentra-
tion of DMSO. After 60 min [methyl-
3H]-thymidine (final concentra-
tion 4 μCi/ml) was added to each well, incubated for 15 min and the
amount of radioactivity incorporated into the cell was determined as
described in Materials and Methods. d Reversibility of menadione-
mediated DNA synthesis inhibition. Mini-units were incubated with
DMSO alone (C) or menadione 50 μM (M) for 60 min with DMEM
containing 4 μCi/ml [methyl-
3H]-thymidine (grey columns) or without
[methyl-
3H]-thymidine (black columns). After incubation, the samples
were processed for measurement of [methyl-
3H]-thymidine incorpo-
ration into DNA (grey columns) or washed, incubated with DMEM
containing 4 μCi/ml [methyl-
3H]-thymidine for 90 min and then
processed for measurement of [methyl-
3H]-thymidine incorporation
into DNA (black columns). All data are the results (mean±SEM) of 2-
3 independent experiments performed by quadruplicate
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neurons). On the other hand, even if available, studies on
cell lines representing each neural cell type will not solve
this problem since they are no representative of intact tissue
due to loss of cell-cell interactions. Future studies on animal
models are needed to address these important issues about
toxicity. Regardless of this issue, strategies to potentiate the
anti-proliferative effect of low menadione concentrations
might help to selectively kill tumor cells. In this context,
the combination of menadione+vitamin C has been ex-
plored in several cancer cell lines with encouraging results
since this combination seems to selectively kill cancer cells
by a novel mechanism of cell death called autoschizis [20,
21]. The cell injury of the menadione+vitamin C has been
associated with oxidative stress that affect the cytoeskeletal
architecture [22]. Additional DNA damage might be caused
by reactivation of DNAse activity that has been found to be
negative in malignant tumors of the central nervous system
[22, 23]. The anti-proliferative effect of menadione has
been studied in several glioma cell lines and showed IC50
values ranging between 13.5 μM to ~25 μM[ 1, 24].W e
recently suggested that drug concentrations much higher
than the IC50 might be required to eliminate 100% of tumor
cells and that the IC50 is not the best parameter to evaluate
anti-cancer drugs because it does not select for useful
clinical drugs [14].
In our study, the IC50 for the DBTRG.05MG human cell
line and other patient derived cells hGCL1-8 were around
10–25 μM but at least one week exposure to 50 μM
menadione alone was necessary to prevent regrowth of
surviving cells. Increasing menadione concentration will
Fig. 2 Anti-proliferative effect of short term incubation with
menadione (M), vitamin C (VC) and menadione:vitamin C (M+VC).
DBTRG-05MG glioma cells were incubated with the indicated
concentration of drugs for 72 h. Cell proliferation was measured by
the CCK kit. Results are representative of two independent experi-
ments performed by quadruplicates
Fig. 3 Menadione:vitamin C
combination inhibit cell prolifer-
ation and prevent regrowth of
human glioma cells at doses
lower than individual drugs.
Anti-proliferative effect of
long -term incubation with
menadione alone (M), vitamin C
(VC) alone or Menadione:vitamin
C at a 1:100 ratio. Top: Expo-
nentially growing cells were
incubated in complete media for
2–3d a y s( a), exposed to
1–25 μM menadione or
0.1–2.5 mM vitamin C for
1w e e k( b-c). During this period
the media and the drugs were
changed twice a week. A clear
decrease in the cell density was
observed by microscopic exami-
nation indicating extensive cell
death (b) followed by a stable
low cell density (c). When the
drug was removed, the surviving
cells resumed proliferation and
formed a monolayer indicated as
regrowth (d). Middle: same as
top but cells were incubated with
menadione 50 μM or vitamin C
5 mM for 1 week. Bottom: same
as top but cells were incubated
with menadione 10 μM+
vitamin C 1 mM for 1 week
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problem, combination with other drugs might selectively
kill cancer cells without increasing toxicity to normal cells.
In the present study, the addition of vitamin C at a 1:100
ratio showed that it is possible to reduce the concentration
of menadione needed to kill 100% of glioma cells from 25–
50 μMt o1 0μM. The combination also reduced the
vitamin C concentration needed to kill 100% of glioma
cells from 5 to 1 mM. Thus, this combination exhibited
anti-tumor activity (cytotoxicity) at concentrations that
were 2.5- to 5-fold lower than for the individual drugs.
As suggested by Matzno et al. [25], the use of lower
menadione concentration is advantageous because it makes
easier to control the useful therapeutic range below toxic
values due to the steepness of the concentration-response
curve (Figs. 2 and 4). In agreement with the literature , anti-
tumor activity at concentrations that were 4- to 61-fold
lower than for the individual vitamins was found in other
types of cancer [26]. However, results from our present data
and those reported should be carefully evaluated consider-
ing methods and experimental designs. For instance, our
values between 2 to 5-fold lower were obtained measuring
regrowth concentration zero (RC0) as endpoint parameter
while the reported values of 4- to 61 –fold values were
Table 1 Regrowth of glioma cells after prolonged treatment with
Menadione (M), vitamin C (VC) or Menadione + Vitamin C (M:VC).
Exponentially growing cells were incubated in complete media for 2–
3 days, exposed to the indicated concentration of menadione , vitamin
C or menadione:Vitamin C for 1 week and evaluated for regrowth
after incubation in drug-free media for 2–4 weeks. (+) and (−)
indicates ability to resume growth when the drug was removed from
the culture media
hGCL1 hGCL2 hGCL3 hGCL4 hGCL5 hGCL6 hGCL7 hGCL8
M( μM ) 1 0 ++++++++
25 +
a − +
a −−+
a −−
VC (mM) 0.1 + + + +++++
2 . 5 ++++++++
M:VC (μM:mM) 10:1 −−−−−−−−
M:VC (μM:mM) 25:2.5 −−−−−−−−
aFew cells were observed
Fig. 4 Menadione alone and menadione:vitamin C showed similar
anti-proliferative potency in a panel of 8 different patients derived
glioma cells. Anti-proliferative effect of short term incubation with
menadione alone (M), vitamin C (VC) alone or menadione:vitamin C
at a 1:100 ratio. hGCL1-8 cells were incubated with the indicated
concentration of drugs for 72 h. Cell proliferation was measured by
the CCK kit
Table 1 Regrowth of glioma cells after prolonged treatment with
Menadione (M), vitamin C (VC) or Menadione + Vitamin C (M:VC).
Exponentially growing cells were incubated in complete media for 2–
3 days, exposed to the indicated concentration of menadione , vitamin
C or menadione:Vitamin C for 1 week and evaluated for regrowth after
incubation in drug-free media for 2–4 weeks. (+) and (−) indicates
ability to resume growth when the drug was removed from the culture
media
Invest New Drugs (2011) 29:1314–1320 1319obtained by determination of CD50 values by the MTT assay
following 1 h treatment [27]. When 5 days continuous
exposure was used, a lower synergistic effect (between 6 to 7
fold lower) was obtained [27]. It is possible that the RC0
may be similar for most cancer cells and only 2.5 to 5-fold
reduction can be obtained for each drug. Due to the
heterogeneous nature of gliomas, the evaluation of several
cell lines is important since some cell lines might show
different sensitivity to a particular drug as it has been
reported for temozolomide [28]. In conclusion, the menadi-
one:vitamin C combination at 10 μM:1 mM may be more
selective against glioma cells and less toxic for normal brain
tissue and should be a strong argument to encourage animal
studies in order to evaluate the anti-proliferative effect on
glioma models in addition to the overall systemic toxicity.
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